Ansuvimab Antibody, Monoclonal | 21-872

Ansuvimab Antibody, Monoclonal | 21-872 | Gentaur UK, US & Europe Distribution

Product Type: Primary Antibodies

Category: Primary Antibodies, Monoclonal Antibodies

Research Area: Drug Analogues

Type: Monoclonal

Host Species: N/A

Reactivity Species: N/A

Homology: N/A

Immunology: Humanized / GP1 surface protein of Ebolavirus

Tested Application: N/A

Application Note: N/A

Positive Control 1: N/A

Positive Control 2: N/A

Predicted Molecular Weight: N/A

Isoform: N/A

Purification: >95%

Clonality: Recombinant Monoclonal

Clone: N/A

Isotype: IgG1

Conjugate: Unconjugated

Physical State: N/A

Buffer: PBS buffer pH 7.5

Concentration: N/A

Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at +4°C short term (1-2 weeks) . Store at -20 °C 12 months. Store at -80°C long term.

Additional Names: N/A

Protein Accession: Q05320

User Note: For research use only .

Background: Responsible for binding to the receptor (s) on target cells. Interacts with CD209/DC-SIGN and CLEC4M/DC-SIGNR which act as cofactors for virus entry into dendritic cells (DCs) and endothelial cells . Binding to the macrophage specific lectin CLEC10A also seem to enhance virus infectivity. Interaction with FOLR1/folate receptor alpha may be a cofactor for virus entry in some cell types, although results are contradictory. Members of the Tyro3 receptor tyrosine kinase family also seem to be cell entry factors in filovirus infection. Once attached, the virions are internalized through clathrin-dependent endocytosis and/or macropinocytosis. After internalization of the virus into the endosomes of the host cell, proteolysis of GP1 by two cysteine proteases, CTSB/cathepsin B and CTSL/cathepsin L presumably induces a conformational change of GP2, allowing its binding to the host entry receptor NPC1 and unmasking its fusion peptide to initiate membranes fusion.

Loading Controls: N/A

Source: XtenCHO

Purity: >95%

CAS: N/A

Shipping Condition: N/A